

Peripheral and lung resident T cell responses against SARS-CoV-2

Judith Grau-Expósito^{1,8}, Nerea Sánchez-Gaona^{1,8}, Núria Massana^{1,9}, Marina Suppi^{1,9}, Antonio Astorga-Gamaza¹, David Perea¹, Joel Rosado², Anna Falcó¹, Cristina Kirkegaard¹, Ariadna Torrella¹, Bibiana Planas¹, Jordi Navarro¹, Paula Suanzes¹, Daniel Alvarez-de la Sierra³, Alfonso Ayora⁴, Irene Sansano⁵, Juliana Esperalba⁶, Cristina Andrés⁶, Andrés Antón⁶, Santiago Ramón y Cajal⁵, Benito Almirante¹, Ricardo Pujol-Borrell^{3,7}, Vicenç Falcó¹, Joaquín Burgos¹, María J. Buzón^{1*}, Meritxell Genescà^{1*}

Affiliations

¹Infectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain;

²Thoracic Surgery and Lung Transplantation Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain;

³Diagnostic Immunology Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain;

⁴Occupational Risk Prevention Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain;

⁵Pathology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Departament de Ciències morfològiques, Universitat Autònoma de Barcelona, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain;

⁶Respiratory Viruses Unit, Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

⁷FOCIS Center of Excellence

⁸These authors contributed equally

⁹These authors contributed equally

*Correspondence: mariajose.buzon@vhir.org (M.J.B.) meritxell.genesca@vhir.org (M.G.)

1 **SUMMARY**

2 Considering that SARS-CoV-2 interacts with the host at the respiratory tract mucosal interface, T
3 cells strategically placed within these surfaces, namely resident memory T cells, will be essential
4 to limit viral spread and disease. Importantly, these cells are mostly non-recirculating, which
5 reduces the window of opportunity to examine circulating lymphocytes in blood as they home to
6 the lung parenchyma. Here, we demonstrate that viral specific T cells can migrate and establish
7 in the lung as resident memory T cells remaining detectable up to 10 months after initial infection.
8 Moreover, focusing on the acute phase of the infection, we identified virus-specific T cell
9 responses in blood with functional, migratory and apoptotic patterns modulated by viral proteins
10 and associated with clinical outcome. Our study highlights IL-10 secretion by virus-specific T cells
11 associated to a better outcome and the persistence of resident memory T cells as key players for
12 future protection against SARS-CoV-2 infection.

13

1 INTRODUCTION

2 We are currently facing a global health emergency, the COVID-19 pandemic. While a great effort
3 is focused on vaccine development, many questions remain unanswered that are necessary to
4 properly manage patients and inform vaccine assessment. To this end, identifying the
5 development of a protective immune response after natural infection and characterizing the
6 correlates of protection would greatly inform on the best strategy to stimulate a protective
7 response by immunization. Moreover, identifying specific immunological parameters capable of
8 predicting disease control (i.e. no hospitalization) could provide new biomarkers to support
9 medical decisions for patients. Most efforts to measure or induce immunity rely on neutralizing
10 antibodies which can certainly limit infection; however, antibody detection is not only inconsistent
11 in infected or convalescent patients^{1, 2, 3, 4} but may also wane with time as shown for other
12 coronaviruses^{5, 6}, although their stability may also depend on the antigen targeted⁷.

13 Virus-specific T cells against SARS-CoV-2 have been shown to develop against
14 coronaviruses^{4, 8, 9, 10, 11, 12, 13, 14} and specific memory T cells persisted in SARS-recovered patients
15 for up to 6 years post-infection⁵. Thus, T cells may potentially provide long-term immunity as
16 demonstrated for other viral infections such as SARS or influenza^{15, 16, 17, 18}. In this sense, mouse
17 models of SARS-CoV-1 infection demonstrated that both CD8⁺T and CD4⁺T cells are critical for
18 viral clearance^{15, 17}. Considering that SARS-CoV-2 interacts with the host at the respiratory tract
19 mucosal interface, T cells strategically positioned within these surfaces, may be essential to
20 limiting infection. A key role for resident memory T cells (T_{RM}) in protection against pathogen
21 challenge has been established for many tissues, including the lung^{5, 17, 19, 20, 21, 22}. These cells,
22 which are strategically located both in the lung airways and in lung interstitial tissue, include CD4⁺
23 and CD8⁺T cells designed to limit re-infections locally. In the context of respiratory infection
24 models such as influenza, CD8⁺T_{RM} have shown to confer cross-protection against different
25 strains²², and both influenza-specific CD4⁺ and CD8⁺T_{RM} have been identified^{16, 23}. Importantly,
26 optimal protection against SARS-CoV-infected mice was conferred by airway memory CD4⁺T
27 cells secreting both, pro-inflammatory interferon gamma (IFN γ) and anti-inflammatory
28 interleukin(IL)-10 molecules¹⁷. Thus, a broader spectrum of T helper (Th) profiles should be
29 included when addressing virus-specific T cells. Further, recruitment of these cells from circulation
30 may depend on the expression of molecules such as chemokine C-X-C motif receptor 3 (CXCR3),
31 which, besides mediating chemotaxis toward inflamed tissue of a biased Th1 profile, appears
32 critical for the recruitment of pulmonary T cells that control infection^{18, 24, 25}. While such recruitment
33 could partially contribute to the decrease of circulating lymphocytes and thus favor tissue
34 infiltration, many other factors may explain the observed lymphopenia associated with COVID-19

1 disease severity^{26, 27, 28, 29}. In this regard, increased susceptibility of both specific and bystander
2 CD4⁺ and CD8⁺T lymphocytes to apoptotic cell death has been observed in other viral infections^{30,}
3 ^{31, 32}, which could be linked to increased glycolysis^{33, 34}.

4 Here, we address several key questions related to early control of SARS-CoV-2 infection
5 mediated by cellular immunity and long-term protection: 1) the functional profile of antigen-specific
6 T cells associated with disease control; 2) if apoptosis is involved in disease severity; 3) if antigen-
7 specific T cell responses have the potential to migrate to the lung and eventually become T_{RM}
8 cells. To this end, we performed detailed phenotypic and functional analyses in clinically-defined
9 groups of patients recruited during the first wave of SARS-CoV-2 infection, including the
10 assessment of T_{RM} in lung of convalescent patients. Informing on the immunological parameters
11 associated with disease control and patient prognosis will aid vaccine development and
12 monitoring of vaccinated individuals towards prediction of immune control.

13

14

15 **RESULTS**

16 **Cohort characteristics**

17 Patients were recruited during the first pandemic wave of SARS-CoV-2 (spring 2020). A total of
18 46 patients were included, in which 14 individuals were symptomatic non-hospitalized cases, 20
19 individuals corresponded to mild-hospitalized cases and 12 to severe-hospitalized cases. Only
20 one patient from the severe group corresponded to a fatal case. Samples were obtained between
21 7-16 days after symptom onset and no differences between groups were detected (Figure S1A).
22 Table S1 shows a summary of the participant characteristics and baseline determinations, in
23 which significant differences are evidenced between the three groups. As previously reported^{26,}
24 ^{28, 29, 35 36}, age, lymphopenia, and biochemical parameters such as D-dimer, IL-6, and ferritin were
25 associated with disease severity. Quantification of the viral load between days 5 and 15 after
26 symptom onset is also reported; however, values between the groups were not statistically
27 significant. Some of the clinical parameters used to stratify mild and severe hospitalized cases
28 are shown in Figure S1B: days to discharge since symptoms onset ($p < 0.0001$), baseline IL-6
29 ($p = 0.008$) and the percentage of oxyhemoglobin saturation in arterial blood /fraction of inspired
30 oxygen (SAFI) ratio at baseline ($p = 0.0052$) and after 48h ($p = 0.0002$). These parameters were
31 used to address associations between immunological parameters and disease severity. In some
32 analyses, 12 control individuals sampled before the COVID-19 pandemic were studied in parallel.

33 To determine if whole plasma cytokine levels in our groups of COVID-19 patients were
34 similar to previously defined patterns reported before^{29, 37, 38, 39, 40}, we analyzed cytokine plasma

1 levels by the ELLA® microfluidics platform in the same samples. Levels of IL-1ra, IL-2, IL-6, IL-
2 10, IL-15, CXCL10 (IP-10), IFN γ , granzyme B and TNF α were elevated in the plasma of
3 hospitalized groups compared to non-hospitalized patients, with higher levels associated with
4 disease severity (Figure S1C). Of note, the deceased patient from the severe cohort (circled in
5 green) had very high levels of some of the molecules associated with severity and fatality
6 prediction, namely IL-6 and IL-1ra^{38, 40}. Further, CXCL10 was the most significant predictor of
7 hospitalization during acute infection, potentially related to impaired T cell responses as
8 suggested¹³. CCL2, also referred to as monocyte chemoattractant protein 1, was significantly
9 higher in the severe-hospitalized group compared to the non-hospitalized patients, while IL-4, IL-
10 7, IL-13, IL-17A, GM-CSF were similar among all three groups of patients (Figure S1C). Strikingly,
11 the levels of IL-12p70 were higher in the plasma of the non-hospitalized compared to the mild
12 COVID-19 group, and the deceased patient had the second lowest level of IL-12p70 of the severe
13 group (0.093pg/mL; Figure S1B).

14

15 **Functional patterns associated to acute infection are defined by disease severity and** 16 **targeted antigen**

17 The functional capabilities of specific CD4⁺ and CD8⁺T cells against SARS-CoV-2 were measured
18 by intracellular cytokine staining in samples ranging from 7 to 16 days-post-symptom onset (mean
19 of 12 days) from all three groups. For that, we stimulated peripheral blood mononuclear cells
20 (PBMC) with overlapping membrane (M), nucleocapsid (N) and spike (S) peptide sets and
21 determined the expression of IFN γ , IL-4, and IL-10, along with the degranulation marker CD107a
22 in CD4⁺ and CD8⁺T cells (Figure S2A and 2B). For each function we calculated the net response
23 for each peptide set (background subtracted) and compared these antigen-specific T cell
24 responses among all three groups (Figure 1A). This way, differences on the frequency of IFN γ -
25 secreting antigen-specific T cells were significantly higher among the hospitalized groups
26 compared to the outpatients (in CD4⁺T cells: p=0.020 for M and S peptides in the mild group;
27 p=0.004 for M, p=0.011 for N and p=0.007 for S peptides in the severe group; Figure 1A). Of note,
28 while non-hospitalized patients did not show a significant increase in the production of IFN γ as a
29 group, some individuals did show an increase in their response (>0.02% after background
30 subtraction) representing 43% of responders, which was lower than the 80% and 92% of
31 responders observed in mild and severe hospitalized groups. In contrast degranulation, measured
32 by CD107a expression, was less detected in general and significance among the groups was only
33 reached in response to M peptides in severe patients compared to non-hospitalized patients
34 (p=0.036) (Figure 1A). We also calculated double positive IFN γ /CD107a CD8⁺T cells, as a

1 surrogate of cytotoxic polyfunctional cells, since double positive cells could be detected in some
2 patients, as exemplified in Figure S2. Interestingly, while the frequency of double positive
3 CD107a⁺IFN γ ⁺CD8⁺T cells responding to the M peptides positively correlated with viral load, the
4 same subset specific for N peptides inversely correlated with baseline levels of IL-6 within the
5 hospitalized cohort (Figure S3A).

6 Assessment of two other functions, IL-4 and IL-10, demonstrated major dominance of
7 these responses based on the cohort and the viral target. A general induction of an IL-4-specific
8 CD8⁺T cell response was observed in response to the viral spike in hospitalized patients
9 compared to the non-hospitalized individuals ($p=0.004$ and $p=0.003$ for mild and severe patients,
10 respectively; Figure 1A). Of note, higher levels of spontaneous secretion of IL-4 (in unstimulated
11 conditions) were observed in hospitalized patients, which essentially correlated with the number
12 of days since symptoms onset to discharge and baseline IL-6 levels (Figure S3B). Moreover,
13 SARS-CoV-2 viral load positively correlated with the overall capacity of CD4⁺T cells to secrete IL-
14 4 in response to TCR independent unspecific activation with PMA/ionomycin (PMA/Io) (Figure
15 S3C). In contrast, the expression of IL-10, a prototypical regulatory cytokine, was significantly
16 increased in CD4⁺T cells from non-hospitalized patients after stimulation with M peptides when
17 compared to the mild COVID-19 group ($p=0.035$; Figure 1A).

18 Correlations between the net frequency of a given function and clinical parameters were
19 consistent with more CD4⁺T cells secreting IFN γ and more CD8⁺T cells secreting IL-4 in response
20 to M and S peptides associated with disease severity (Table S2). Even the total CD4⁺ or CD8⁺T
21 cell IFN γ response and the total IL-4 secretion by CD8⁺T cells against any of the three viral
22 proteins (all peptides) correlated with more days at the hospital for IFN γ or with other clinical
23 parameters for IL-4 (Table S2). Further, antigen-specific CD4⁺T cells degranulating in response
24 to all viral peptides and, in the case of CD8⁺T cells, in response to M peptides also correlated with
25 higher levels of IL-6 (Table S2). In contrast, the percentage of M-specific CD4⁺T cells secreting
26 IL-10 correlated with better prognosis in all clinical parameters (Table S2) and for N-specific
27 positively with better oxygenation at 48h (Table S2).

28 Actually, when the overall response, including all functions, was represented as donut
29 charts displaying the mean frequency of responses including all individuals (responders and non-
30 responders), differences among groups in response to each peptide set were emphasized (Figure
31 1B). This was, M peptides were shown to mostly stimulate IL-10 secretion in non-hospitalized
32 patients, while in hospitalized cases, increasing amounts of IFN γ for CD4⁺T cells and of IL-4 and
33 degranulation for CD8⁺T cell were observed (Figure 1B). In addition, N peptides induced higher
34 frequencies of antigen-specific CD8⁺T cells degranulating in mild and non-hospitalized cases,

1 while S peptides stimulated IL-4 secretion mainly in the hospitalized groups (Figure 1B). Overall,
2 our analyses indicated, on one hand, group-based differences, where a dominance of IL-4 and
3 IFN γ SARS-CoV-2-specific responses were associated with disease severity and of IL-10 to
4 minor disease; on the other hand, we observed targeted protein based-differences, where M and
5 N peptides induced a Th1 profile exemplified by IFN γ in CD4⁺T cells and degranulation (CD107a)
6 in CD8⁺T cells, respectively, and S peptides induced a biased Th2 profile exemplified by IL-4.
7 This pattern was shown in an exaggerated manner in the deceased patient, in which IL-10
8 responses were absent and IL-4 together with some IFN γ dominated antigen-specific responses
9 (Figure 1C).

10

11 **Expression patterns of chemokine receptors associated to SARS-CoV-2-infected patients**

12 Next, we aimed to determine if part of the specific T cell response was potentially migrating
13 towards the infected tissues by assessing the proportion of CCR7 and CXCR3 expression within
14 the same analyses. In peripheral blood, CCR7 distinguishes T cells homing to lymph node (LN)
15 when expressed, or effector memory (EM) T cell subsets migrating to tissues when absent⁴¹,
16 while CXCR3 may help define antiviral T cells infiltrating inflamed tissues, including the lung
17 parenchyma²⁵. CD4⁺T cells showed only two evident subsets in most patients based on CCR7
18 expression, since CXCR3 was homogeneously dimly expressed in these two subsets (Figure
19 S2A) and no differences between the different study groups were observed (Figure 2A). In
20 contrast, CD8⁺T cells presented five subsets based on these chemokine receptors (Figure S2A
21 and 2C), and significant differences among the groups were observed (Figure 2B). Non-
22 hospitalized patients showed increased frequencies of CCR7^hCXCR3^dCD8⁺T cells, while severe
23 patients presented increased frequencies of EM CCR7⁺CXCR3⁺T cells ($p=0.0012$ and $p=0.0034$
24 respectively, Figure 2B and 2C). In fact, the accumulation of CCR7^hCXCR3^dCD8⁺T cells indicated
25 good prognosis and negatively correlated with the number of days to discharge since symptoms
26 onset and with IL-6 levels at hospital entry (Figure 2D), while the frequency of EM CXCR3⁺ CD8⁺T
27 cells significantly correlated with disease severity parameters (Figure 2E).

28 We then focused on the distribution of the net antigen-response for each peptide and
29 cohort among these CCR7/CXCR3 subsets. Overall, antigen-specific CD4⁺T cells showed a
30 distinct pattern based on the function assessed: IFN γ , degranulation (CD107a) and IL-4 were
31 significantly associated to EM CXCR3⁺ CD4⁺T cells across the different groups and proteins, while
32 IL-10 was associated to the LN-homing fraction (CCR7⁺CXCR3⁺) in response to M and N protein
33 peptides in the non-hospitalized group (Figure 3A). Of note, in general, most individuals in the
34 hospitalized groups also showed this trend for the IL-10 response, although statistical significance

1 was not reached as a group. Moreover, several subsets out of these antigen-specific CD4⁺T cells,
2 mostly the ones secreting IFN γ or IL-4, correlated with worse prognosis in the clinical parameters
3 assessed before, and some examples are shown in Figure 3B-3E. In general, stronger
4 associations were observed within the CCR7⁺CXCR3⁺ subset, which correlated with severity,
5 except if this subset was secreting IL-10 against M peptides (Figure 3F). Moreover, SARS-CoV-
6 2 viral load was negatively associated with the overall capacity of EM CXCR3⁺ CD4⁺T cells to
7 secrete IL-10 in response to TCR independent unspecific activation with PMA/Io (Figure 3G).

8 In the analyses of the proportion of antigen-specific CD8⁺T cells in each CCR7/CXCR3
9 subset, we did not consider the EM CXCR3⁻ subset, which represented <1% in most patients
10 (Figure 2B). As expected, IFN γ antigen-specific CD8⁺T cells were more frequent among the
11 CXCR3⁺ subsets, with some individual exception, such as N-specific CCR7⁺CXCR3⁻ T cells within
12 the non-hospitalized group (Figure S4A). Further, IFN γ secreting CCR7^hCXCR3^dCD8⁺T cells in
13 response to N peptides correlated negatively with days to hospital discharge (Figure S4B).
14 Degranulation, which was enhanced also after N stimulation, was unexpectedly detected in all
15 CD8⁺ CCR7/CXCR3 subpopulations (Figure S5A). Though only in the LN-homing
16 CCR7⁺CXCR3⁺CD8⁺T cell subset in response to S peptides, degranulation was associated with
17 higher viral load (Figure S5B). With respect to IL-4 secreting antigen-specific CD8⁺T cells, in
18 general these responses were more frequent in CCR7⁺ LN-homing subsets, and as mentioned
19 before, they increased with disease severity (Figure S6A). Consequently, the frequency of IL-4
20 detected in response to M or S peptides in several of these fractions correlated with disease
21 severity (Figure S6B). Remarkably, SARS-CoV-2-specific CD8⁺T cells secreting IL-10 were
22 strongly represented among the CCR7^hCXCR3^d subset, reaching statistical significance in
23 response to any of the viral proteins within the mild disease cohort and in response to N peptides
24 in non-hospitalized patients, but not in the hospitalized group with severe disease (Figure 4A).
25 Finally, we detected two additional correlations within the CD8⁺T cell compartment that were of
26 interest: overall antigen-specific EM CXCR3⁺ CD8⁺T cells correlated with higher viral loads if
27 responding to M peptides (Figure 4B), while the same subset responding to N peptides negatively
28 correlated with IL-6 (Figure 4C). All together, these results demonstrate individual migratory
29 patterns associated with a given function: whilst most of the functions assessed here were
30 associated with lung homing subsets (CCR7⁻), IL-10-specific T cells expressed high levels of
31 CCR7. In fact, a strong association towards better disease prognosis was established for an
32 increased proportion of CCR7^hCXCR3^d CD8⁺T cells, which represented a major constant source
33 of IL-10 in CD8⁺T cells. Further, antigenic stimulation could be driving CCR7⁻ effector immune

1 responses towards the lung, yet under uncontrolled disease progression, such effector functions
2 seemed to increase in LN-homing CCR7⁺ subsets.

4 **Apoptosis is enhanced in antigen-specific and non-specific T cells during severe infection**

5 We included caspase-3 in the flow cytometry panel as a surrogate marker of apoptotic cell death
6 activation⁴², which was quantified in both antigen-specific and bystander T cells from the different
7 subsets of the study groups (Figure 1A). Overall expression of caspase-3 in response to
8 stimulation was increased in total CD4⁺T cells of the severe group after M and PMA/Io stimulation
9 ($p < 0.0001$ and $p = 0.032$, respectively) and in CD8⁺T cells after S stimulation in comparison to the
10 non-hospitalized group ($p = 0.0009$) (Figure 5A). Moreover, caspase-3 expression in CD4⁺ and
11 CD8⁺T cells after stimulation with S-peptides positively correlated with baseline IL-6 and with the
12 number of hospitalization days for CD8⁺T cells (Figure 5B). In addition, the overall frequency of
13 CD4⁺T cells expressing caspase-3 in response to PMA/Io positively correlated with viral load
14 (Figure 5B). Further, an increased expression of caspase-3 within the CCR7^hCXCR3^d subset was,
15 in general, linked to the disease severity (Figure 5C), reaching statistical significance after PMA/Io
16 stimulation when comparing the severe and the non-hospitalized groups ($p = 0.031$; Figure 5C).
17 Consequently, those frequencies in response to stimulation (N, S or PMA/Io) correlated positively
18 with the number of days at the hospital and with baseline IL-6 (Figure 5D). Expression of caspase-
19 3 in other CCR7⁺CD8⁺T cell subsets in response to N and S peptides also correlated with IL-6
20 baseline levels in patients (Figure 5D).

21 Regarding antigen-specific T cells we detected remarkable differences within the IL-10
22 secreting T cells. In this sense, increased expression of caspase-3 was distinguished in the
23 hospitalized severe group compared to the non-hospitalized in S-specific IL-10⁺ CD4⁺T cells
24 ($p = 0.004$), N-specific IL-10⁺ CD8⁺T cells ($p = 0.016$) and even in the overall IL-10 secretion
25 capacity in response to PMA/Io response ($p = 0.031$ for CD4⁺ and $p = 0.006$ for CD8⁺; Figure 5E).
26 Further, significant correlations between apoptosis in IL-10 antigen-specific T cells and several
27 clinical parameters supported these results (Figure 5F). As for the other functions, we only
28 detected positive correlations for the expression of caspase-3 in baseline and N-specific CD107a⁺
29 CD4⁺T cells with viral load and IL-6 levels, respectively (Figure 5G). These results indicate
30 increased activation-induced cell death associated with viral replication and disease severity
31 affecting total CD4⁺ and CD8⁺T cells, a phenomenon that seems to be modulated by the viral
32 protein targeted. Moreover, CD8⁺CCR7^hCXCR3^d T cells, a major producers of IL-10, appeared to
33 be one of the most affected population.

34

1 **Ag-specific T_{RM} responses are present in the lung of convalescent patients**

2 In order to demonstrate that antigen-specific T cells detected during acute SARS-CoV-2 infection,
3 not only migrate into the lung parenchyma but also persist as T_{RM}, we measured their frequency
4 in lung biopsies of five patients. These patients, who strongly differed in their SARS-CoV-2
5 infection profile, successfully recovered and SARS-CoV-2 was not detected in the respiratory tract
6 by RT-PCR before they underwent thoracic surgery for different reasons. Briefly, HL24 patient
7 was a young-asymptomatic patient whose blood and lung samples were analyzed 21 days after
8 SARS-CoV-2 laboratory-confirmation by RT-PCR. In contrast, samples were analyzed between
9 6 and 10 months after initial SARS-CoV-2 RT-PCR confirmation for the two mild cases (HL52 and
10 HL65) and the two severe cases (HL27 and HL69). Of note, a more detailed COVID-19 clinical
11 history can be found in the methods section.

12 Antigen-specific T cell responses were analyzed in total lung CD4⁺ and CD8⁺T cells and
13 by three different fractions: CD69⁻ (non-T_{RM}), CD69⁺ (T_{RM}) and a subset within CD69⁺ cells
14 expressing CD103⁺ (T_{RM} CD103⁺) (Figure S7A). Of note, CD69⁺T cells did not express T-bet
15 confirming their T_{RM} nature²⁰. As shown for one of the convalescent patients with previous severe
16 disease (HL27; Figure 6A), antigen-specific T cells secreting IFN γ were restricted to the T_{RM}
17 fractions, which in the case of S-specific CD4⁺T cells represented up to 3.47% of the T_{RM}CD103⁺
18 subset. Similarly, in the lung biopsy of a mild convalescent patient (HL52; Figure 6B) N-specific
19 CD8⁺T cells secreting IFN γ were restricted to the T_{RM} fractions and >40% of them were
20 simultaneously degranulating (CD107a⁺). In fact, the assessment of the frequency of cells
21 responding to each peptide pool demonstrated a general trend for more antigen-specific T cells
22 belonging to the T_{RM} subsets for all functions and all patients (Figure 6C and S7B-F). Regardless
23 of the variability observed among study patients, the frequency of specific T cell responses
24 increased with disease severity (from left to right; Figure 6C), while their magnitude was in general
25 low and less consistent for IL-4 or IL-10 responses (Figure 6C and S7B-F). Importantly, a
26 consistent polyfunctional IFN γ ⁺CD107a⁺ T cell response, which represented between 0.025 and
27 0.051% of all CD3⁺T cells and was mostly associated with the T_{RM} fraction (>75%), was detected
28 against N peptides in all patients except in the asymptomatic one (HL24; Figure 6D).

29 The comparison between the overall SARS-CoV-2-specific T cell responses detected in
30 lungs with the ones found in contemporary peripheral blood samples highlighted strong
31 differences between these two compartments (Figure 7). For example, in the asymptomatic HL24-
32 patient IFN γ and IL-10 responses were more frequent in blood than in lung, IL-4 was absent, and
33 T cell degranulation was only detectable in lung (Figure 7A). Importantly, this patient was closer
34 to the initial RT-PCR-based laboratory confirmation (3 weeks after), and his profile was more

1 consistent with a non-hospitalized patient. A different pattern was observed for one of the severe
2 convalescent patients (HL27), who had persistent T_{RM} in the lung overrepresented by S-specific
3 $CD4^+$ T cells secreting IFN γ , which represented up to 1.58% of the total $CD4^+$ T cells, while only
4 0.082% of the circulating $CD4^+$ T cells secreted IFN γ and, in this case, in response to M peptides
5 (Figure 7E). In fact, whereas all four functions were detected in T cells from lung after 6 months
6 since initial infection for this patient, they were barely detectable in blood. Overall, viral-specific
7 T_{RM} responses were detected in all patients. However, no consistent patterns were observed
8 among patients in terms of viral proteins targeted and functions between blood and lung
9 compartments, except for the polyfunctional response detected in tissue against N peptides. Of
10 note, the asymptomatic patient had no detectable antibodies, whilst the two severe and two mild
11 patients had detectable antibodies against SARS-CoV-2 in a concomitant plasma sample
12 (measured as total and as IgG fraction). Furthermore, no virus was detected in any of the lung
13 biopsies by immunofluorescence or viral RNA in situ hybridization. Overall, our results highlight
14 the establishment and persistence of lung-resident T cell immunity against SARS-CoV-2 viral
15 infection. However, in most cases, antigen-specific T_{RM} patterns could not be identified in T cells
16 from blood.

17
18

19 **DISCUSSION**

20 This study identifies unique features of the cellular immunological response against SARS-CoV-
21 2 relevant to infection control and disease progression, which may be critical to informing vaccine
22 assessment and development of new prototypes. First of all, we show that the acute response of
23 non-hospitalized infected patients is characterized by $CD4^+$ and, to less extent, $CD8^+$ SARS-CoV-
24 2 specific T cells secreting IL-10, to which subsets expressing high levels of CCR7 contribute
25 abundantly. In contrast, hospitalized patients show a bias towards an effector response
26 characterized by IFN γ and IL-4 secretion, being the main functions as severity increases. Second,
27 depending on the SARS-CoV-2 viral protein targeted, different $CD4^+$ and $CD8^+$ T cell functional
28 profiles are generated, which have clear implications for vaccine design. Third, lymphopenia is
29 partially a consequence of increased apoptosis in antigen-specific and non-specific T cells, which
30 is associated with disease severity and where SARS-CoV-2 specific subsets, such as IL-10
31 secreting T cells, appear to be more susceptible. Lastly, and most important, SARS-CoV-2 T_{RM}
32 can be established and persist for 10 months after infection; nonetheless, the magnitude and
33 profile of the lung SARS-CoV-2 specific T cells strongly differ from the response detected in blood.

1 Major efforts have recently centered on the identification and characterization of SARS-
2 CoV-2 specific T cells^{4, 8, 9, 10, 11, 12, 13, 14}. Several of these studies have focused on defining the viral
3 proteins more often targeted by specific T cells, concluding that after infection a broad cell
4 response against multiple structural and non-structural regions of SARS-CoV-2 is detected in
5 most convalescent patients^{4, 9, 12}. More recently, it has been reported that SARS-CoV-2 specific
6 T cells appear to be weaker and less frequent during acute infection¹³. In this sense, in our study,
7 while the frequency of responders based on CD4⁺T cells specifically secreting IFN γ was similar
8 to previous reports, they were indeed weak in terms of the amount of IFN γ or cytotoxicity.
9 However, SARS-CoV-2-specific T cell response during acute infection appeared to be dominated
10 by IL-4 secretion in hospitalized patients and by IL-10 in non-hospitalized patients. A recent report
11 highlights that, in contrast to other cytokines, increased levels of SARS-CoV-2 specific CD4⁺T
12 cells secreting IL-10 were mainly detected during active disease⁴³. However, these functions have
13 rarely been assessed as part of the specific intracellular T cell response, and others have
14 measured IL-4 in the supernatant of stimulated PBMC without detecting any increase^{9, 13, 14}. In
15 contrast, higher serum levels of IL-4, IFN γ and IL-10 cytokines, among others, have been
16 associated with COVID-19^{29, 36, 37, 39}. Differences in methodology and sample timing may account
17 for these discrepancies. In fact, we did not detect changes in plasma levels of IL-4, highlighting
18 differences between measuring the overall level of a given cytokine released systemically rather
19 than the capacity of a small frequency of antigen-specific T cells to quickly secrete such cytokine.
20 Importantly, several studies have detected a negative impact of IL-4 mediated responses on
21 immune protection⁴⁴. Furthermore, an increased expression of IL-4 was detected in the lungs of
22 patients who died from SARS-CoV-2 infection⁴⁵. In our cohort, spontaneous IL-4 secretion from
23 both T cell subsets correlated with disease severity, and responses against the spike protein
24 strongly stimulated this response, potentially suggesting the induction of a stronger antibody-
25 directed response. Last, the patient with mild infection who tested positive for 4 months (HL65)
26 showed the most frequent IL-4 response in the lung, which was against S peptides.

27 Caspase-mediated apoptosis in the immune system is a major contributor to immune
28 homeostasis in a process termed activation-induced cell death⁴⁶, which could potentially
29 contribute to minimize an overwhelming cytokine response. Our results are consistent with
30 apoptosis significantly contributing to the lymphopenia detected in COVID-19 patients, and the
31 preferential loss of CD8⁺T cells is accompanied by an increase in caspase-3 within this
32 compartment, consistent with a pre-publication⁴⁷. Since inflammatory molecules can often be
33 potent activators of cell death, increasing levels of IL-10 may moderate the extent of apoptosis
34 induced, as occurs in mouse models of bacterial infection⁴⁸. Moreover, not only may the

1 inflammatory environment contribute to a higher proportion of bystander T cells succumbing to
2 apoptotic cell death, but viral proteins may also induce apoptosis in both antigen and non-antigen
3 specific T cells. While effector T cells with degranulation capacity are expected to be more
4 terminally differentiated and, consequently, may be more prone to activation-induced cell death,
5 the fact that other subsets (i.e. CCR7^hCXCR3^d/IL-10 secreting) were more affected is intriguing
6 and requires further study.

7 Critically, the only cytokine that was higher in non-hospitalized compared to hospitalized
8 groups was IL-12p70 (Figure S1B), suggesting that, as occurs with other respiratory viruses⁴⁹,
9 cell-mediated Th1 immunity is necessary for recovery from respiratory infection. A general
10 predominance of a Th1 profile does not compromise the generation of neutralizing antibodies⁴⁴.
11 Further, it is increasingly accepted that Th-cell subsets are plastic, especially during responses
12 to pathogens *in vivo*, and even cytokines such as IL-10 can be produced by subpopulations of
13 cells within multiple effector subsets⁴⁴. However, SARS-CoV-2-specific T cells from acute
14 responders demonstrated a biased Th1 profile, where IFN γ -secreting T cells could also secrete
15 IL-2 in the case of CD4⁺ and TNF α and granzyme B, but not IL-10, in the case of CD8⁺¹³. Our
16 data also shows marginal co-expression between IFN γ , IL4 and IL-10, suggesting multiple
17 polarizations of antigen-responding T cells⁴⁴, which is also supported by different CCR7/CXCR3
18 subsets being the main contributors to a given response. Moreover, this polarization was partially
19 induced by the targeted protein, where M peptides induced the strongest IFN γ secretion in CD4⁺T
20 cells, N peptides enhanced cytotoxicity in CD8⁺T cells and S peptides had an overall predominant
21 Th2 profile (IL-4). Similar to what was observed for convalescent patients⁹, M and N-specific
22 responses dominated in non-hospitalized and mild hospitalized cases, indicating that a candidate
23 vaccine including only SARS-CoV-2 spike would limit the array of responses during natural
24 infection⁹. Furthermore, a comparison between the functional profile of antigen-specific CD4⁺ and
25 CD8⁺T cells based on the viral protein targeted evidenced a wider functional profile for CD8⁺T
26 cells targeting M or N peptides compared to S, which was more often observed in milder cases
27 than in severe ones¹² and agrees with recent identification of responses to frequently recognized
28 CD8⁺T cell epitopes⁵⁰. Overall, our results concur with a broader Th profile in CD8⁺T cells induced
29 by the non-spike viral proteins and associated with a less severe infection, while spike responses
30 dominated by IL-4⁺ CD8⁺T cells represented a hallmark of disease severity, being the sole
31 response in the fatal case. Further, the observation that N-specific EM CXCR3⁺CD8⁺T cell
32 responses with an IFN γ ⁺CD107a⁺ Th1 profile were associated with non-hospitalization during
33 symptomatic COVID-19 suggests a favorable immune response when the N protein is targeted
34 by CD8⁺T cells and these responses can migrate towards infected tissues. The CXCR3-CXCL10

1 axis appears critical for the recruitment of CD4⁺ and CD8⁺T cells that control influenza and
2 tuberculosis infection in the lung respectively^{25, 51}. Consequently, lung-T cell recruitment may
3 partially contribute to the lymphopenia detected in patients⁵², where this antiviral response will
4 likely establish as resident memory cells. In fact, N-specific IFNγ⁺CD107⁺ T_{RM} were detected in all
5 four convalescent patients 6 to 10 months after infection.

6 Recent deep immune profiles of COVID19 patients have identified T-bet expression as a
7 transcriptional factor associated to patients with better prognosis⁵³. Importantly, T-bet is not only
8 a key regulator of Th1 immune effector responses and CXCR3 expression, essential for effective
9 clearance of pathogens and maintenance of immunity⁵⁴, but also crucial for migration, proliferation
10 and survival of T regulatory cells (Treg) during Th1-mediated immune responses *in vivo*⁵⁵. Indeed,
11 CXCR3 is also found on a subset of CD4⁺Foxp3⁺T cells, and the control of inflammatory
12 responses at mucosal surfaces requires IL-10 producing Treg⁵⁵. One of the main correlates of
13 disease control during acute infection was IL-10 secretion, which dominated the specific immune
14 response of non-hospitalized patients. Two previous studies have detected reduced frequencies
15 of Treg in severe COVID-19 cases^{26, 56}; however, IL-10 was detected in supernatants from
16 stimulated PBMC of severe patients during acute infection¹⁴, and a similar trend was observed in
17 a cohort of acute patients with a wider range of sampling days, 4-37¹³. While, as detected in the
18 plasma of our own cohort of patients, increased serum levels of IL-10 have been widely
19 associated with COVID-19 and disease severity (reviewed in³⁷), several factors may explain these
20 results. The plasma source of IL-10 can have multiple cellular origins, ranging from myeloid
21 subsets to epithelial cells, since not only may almost all leukocytes produce IL-10, but also the
22 range amplifies during inflammation⁴⁸. The systemic increase in IL-10 may still act as a
23 compensatory response to limit massive ongoing inflammation in severe patients⁵⁷. We propose
24 that an early effector specific T cell response coordinated with engagement of other immune
25 profiles limiting inflammation may aid at promoting infection resolution. This notion is supported
26 by comprehensive analyses of common immune correlates of protection from mortality in mouse
27 models of influenza and SARS-CoV infection, which revealed a unique T regulatory suppressive
28 profile that contributed to this balance⁵⁸. Furthermore, it has previously been shown that Treg
29 activity is required during viral infections to allow for appropriate generation and migration of
30 immune effector cells to the site of infection^{59, 60}, while blocking the action of the IL-10 secreted
31 by antiviral T cells results in enhanced pulmonary inflammation and lethal injury^{17, 48, 61}. In fact,
32 during influenza infections, type I IFN signaling may contribute to IL-10-producing lymphocyte
33 recruitment to the site of infection to moderate excessive inflammation, which will be coincident
34 with the onset of the adaptive immune response⁴⁸, being CD8⁺T cells a primary source of IL-10

1 production in the respiratory tract⁶². Accordingly, while IL-10 plasma levels increased with disease
2 severity, the fatal case had one of the lowest levels in plasma, which was accompanied by an
3 absolute lack of IL-10 secretion by antigen-specific T cells.

4 T_{RM} strategically residing in peripheral tissues are key to controlling mucosal infections
5 and providing rapid and durable immunity against reinfection^{20, 63}. Previous studies in SARS-
6 recovered patients already pointed towards persistence of a memory T cell response for up to 6
7 years after infection, and suggested vaccine-mediated induction of T_{RM} as a long-term protection
8 strategy⁵. In concordance, a larger proportion of CD8⁺T cell effectors with T_{RM} characteristics were
9 present in bronchoalveolar lavages from patients with moderate infection compared to severe-
10 infected patients⁶⁴. We indeed report the existence of a high frequency of T_{RM} in the lung of a
11 patient who was infected almost 6 months before, yet had a severe and durable infection (HL27).
12 In this patient, while all functions were represented in T_{RM} in a remarkably higher proportion than
13 in blood, IFN γ in response to S peptides dominated. In this sense, particularly high frequency of
14 spike protein-specific CD4⁺T cell responses was observed in blood in patients who had recovered
15 from COVID-19^{4, 9, 12}. Importantly, CD4⁺T cells are necessary for the formation of protective
16 CD8⁺ T_{RM} during influenza infection, and cytokines, such as IFN γ , are necessary signals for this
17 process²⁰. However, CD4⁺T cells themselves can be cytotoxic and, actually, have been shown to
18 confer protection against influenza²⁰. We also detected degranulation in response to viral peptides
19 in CD4⁺ and even more so in CD8⁺T cells from the lung, which in the case of the asymptomatic
20 young patient were completely absent in blood. Lack of degranulation in blood from convalescent
21 patients has also been reported¹². Further, the fact that the lung biopsy of this young
22 asymptomatic patient was at 3 weeks RT-PCR laboratory-confirmation of infection, suggests early
23 recruitment of cytotoxic T cells to the lung even in asymptomatic cases. Moreover, the most
24 frequent responses by circulating T cells from this asymptomatic patient were CD4⁺ and CD8⁺T
25 cells secreting IL-10, which concurs with the dominating pattern in non-hospitalized patients
26 during acute infection.

27 We acknowledge that our study has several limitations, one being that sample size for the
28 different groups was small to be conclusive. However, this was compensated by a narrow window
29 of sampling during acute infection (7-16 days, post-symptoms onset) and by a comprehensive
30 clinical characterization to stratify patients to study groups. In this sense, multiple correlations
31 support our main findings and provide strength to our data, which is also largely supported by
32 current literature. Further, identification of the precise phenotypes generating antigen-specific T
33 responses, such as Tregs for IL-10, or the consideration of other T lymphocytes such as gdT cells
34 should also be considered in future studies. Last, only five lung biopsies obtained from very

1 different COVID-19 convalescent patients could be studied. While these patients are so far
2 scarce, the immune responses identified in those samples not only contributed to round out the
3 present report, but also represent the first evidence to our knowledge of persisting SARS-CoV-2-
4 specific T_{RM} in the lung. Disease severity during acute SARS-CoV-2 infection is associated with
5 strong peripheral T and B cell responses^{4, 27}, which not only may relate to antigenic burden but,
6 also could potentially translate into a significant proportion of antigen-specific T_{RM} in the lung once
7 the patient recovers. Remaining important questions concern the level of viral replication and
8 associated symptomatology that will stimulate an effective immune response at the respiratory
9 tract, and also, how quick this response will be established. However, the fact that an
10 asymptomatic patient had degranulating antigen-specific T cells in the lung 3 weeks after infection
11 is at least encouraging. Overall, a balanced effector/anti-inflammatory response may be key for
12 early viral containment, where antigen-specific IL-10⁺T cells could be determinant in limiting
13 inflammation. Thus, the possibility that overstimulated pro-inflammatory T cells contribute to
14 disease severity cannot be ruled out. Our findings encourage next-generation vaccine designs to
15 consider including viral proteins beyond the spike protein, in particular nucleocapsid peptides,
16 which should broaden and balance the functional profile of memory T cells, resembling control of
17 natural infection.

18
19

20 **METHODS**

21 **Ethics statement**

22 This study was performed in accordance with the Declaration of Helsinki and approved by the
23 corresponding Institutional Review Board (PR(AG)192/2020 and PR(AG)212/2020) of the Vall
24 d'Hebron University Hospital (HUVH), Barcelona, Spain. Written informed consent was provided
25 by all patients recruited to this study and samples were prospectively collected and cryopreserved
26 in the Vall d'Hebron Research Institute.

27

28 **Healthy donors**

29 Blood samples from healthy adult donors were obtained via phlebotomy. These blood samples
30 were collected for studies unrelated to COVID-19 between September 2018 and June 2019
31 (PR(AG)116/2018 and PR(AG)117-2018). At the time of enrollment in the initial studies, all
32 individual donors provided informed consent that their samples could be used for future studies.
33 These samples were considered to be from unexposed controls given that SARS-CoV-2 emerged
34 as a novel pathogen in December 2019 and these samples were largely collected before this

1 date. These donors were considered healthy in that they had no known history of any significant
2 systemic illnesses. The cohort of healthy donors includes 12 individuals.

3

4 **Patients with SARS-CoV-2 infection**

5 Adult patients, 18 years old and older, diagnosed with acute COVID-19 were recruited at the Vall
6 d'Hebron Hospital during the first COVID-19 outbreak between March and May 2020. Diagnosis
7 of acute COVID-19 was defined by symptomatology and/or clinical findings and confirmed by
8 positive reverse-transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2 in a
9 respiratory tract specimen. Immunocompromised patients in which the immune response may be
10 affected were excluded of the study. 20 milliliters of blood were collected at baseline by
11 phlebotomy in two EDTA tubes and stored at room temperature briefly prior to processing for
12 PBMC and plasma isolation. Samples were obtained between 7 and 16 days after symptoms
13 onset.

14 Biochemistry analyses were measured at baseline in all patients and, subsequently,
15 according to the clinical care needs of each patient during infection. Routine clinical laboratory
16 analyses included complete blood count, coagulation testing (including D-dimer measurement),
17 liver and renal function, electrolytes and inflammatory profile (including C-reactive protein,
18 fibrinogen, ferritin and IL-6). The study cohort consisted of 12 patients with severe disease, 20
19 with mild disease and 14 non-hospitalized individuals. Patient information is summarized in Table
20 S1. According to disease severity patients, at the discretion of the treating physician, patients
21 were classified in three groups:

22 a) Patients with severe disease: individuals with radiologically confirmed pneumonia that
23 required hospitalization and had acute respiratory failure and/or analytical parameters of severity
24 and/or extensive radiological involvement.

25 b) Patients with mild disease: individuals with radiologically confirmed pneumonia that
26 required hospital admission but without criteria of severity.

27 c) Non-hospitalized patients: individuals without pneumonia and with pauci-asymptomatic
28 disease that did not require hospitalization and managed on an outpatient clinic.

29 Data were collected prospectively from the medical charts of the patients. We collected
30 sociodemographic characteristics, past medical records, Charlson comorbidity score,
31 concomitant medication, treatments against SARS-CoV-2 infection, adverse drug events, blood
32 test results, imaging studies, microbiological tests and supportive measures needed. Vital signs,
33 symptoms and physical examination were recorded. Laboratory, microbiology and imaging
34 studies were performed according to the clinical care needs of each patient.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

Lung biopsies

Lung biopsies were obtained from five patients recovered from SARS-CoV-2 infection who needed a lung resection. Analyses were performed using healthy areas from the lung resection. HL24 sample corresponded to a young smoking man (in his early 20') who had detectable viral load by RT-PCR without symptoms, followed by two negative RT-PCR measurements (8 and 18 days after the positive result). He underwent surgery for pneumothorax 21 days after the positive SARS-CoV-2 detection. HL52 corresponded to an ex-smoker man in his late 70' who was hospitalized for five days due to symptomatology compatible with SARS-CoV-2 infection (with confirmatory RT-PCR 3 days after hospitalization and a baseline IL-6 of 26.15 pg/mL). During a post-COVID examination, a lung carcinoma was diagnosed, which instigated thoracic surgery 7.5 months after hospital discharge. HL65 was a woman in her early fifties hospitalized for three days (without oxygen requirements), with confirmatory SARS-CoV-2 RT-PCR and a baseline IL-6 of 5.25 pg/mL. During the next 4 months, she tested positive for RT-PCR. She underwent thoracic surgery for a pulmonary nodule 2 months after testing negative for RT-PCR (and 6 months after initial discharge). HL69 was a man in his late sixties hospitalized for severe COVID-19 for 35 days (baseline IL-6 of 34.66 pg/mL) and treated for the symptomatology derived of the SARS-CoV-2 infection (with confirmatory RT-PCR). During a post-COVID examination, a pulmonary nodule was diagnosed, which instigated thoracic surgery 10 months after initial infection. HL27 was an ex-smoker man in his late sixties who was hospitalized for one month due to respiratory insufficiency caused by SARS-CoV-2 infection (with confirmatory RT-PCR and a baseline IL-6 of 133.7pg/mL). One month after discharge, he presented a rash in photoexposed skin, potentially related to persistent SARS-CoV-2 infection⁶⁵ or treatment with hydroxychloroquine⁶⁶. RT-PCR for SARS-CoV-2 tested positive again, turning into a RT-PCR negative two weeks after. During this time, a lung carcinoma was diagnosed, which instigated thoracic surgery 3 months after the negative RT-PCR (and 5 months after initial discharge).

Concomitant to the lung biopsy, blood samples were also collected. Thus analyzed paired blood and tissue samples corresponded to 21 days after the first positive SARS-CoV-2 detection for the HL24 patient (asymptomatic) and between 6 and 10 months after initial infection for HL65 (mild), HL52 (mild-PCR+ for 4 months), HL69 (severe) and HL27 (severe-PCR+ for 2 months) patients. Blood samples were immediately processed for PBMC and serum isolation, which was used for SARS-CoV-2 antibody detection.

SARS-CoV-2 RT-qPCR

1 Upper (naso/oropharyngeal swabs) and lower (bronchoalveolar lavage, tracheal aspirate, sputum
2 or bronchoaspirate) respiratory tract specimens from subjects with suspicion of COVID-19 were
3 received and tested at the Respiratory Viruses Unit of the Microbiology Department of the HUVH.
4 COVID-19 diagnosis was performed by two commercial RT-PCR-based assays, Allplex™ 2019-
5 nCoV (Seegene, Korea) or Cobas® SARS-CoV-2 (Roche Diagnostics, USA) tests. In addition, an
6 in-house PCR assay using the primer/probe set targeting the nucleocapsid protein (N1) and the
7 human RNase P (housekeeping gene), from the CDC 2019-nCoV Real-Time RT-PCR Diagnostic
8 Panel (Qiagen, Hilden, Germany), was performed. In order to minimize variations due to a non-
9 standardized collection of a heterogeneous specimen, the Ct values of the viral target were
10 normalized to the housekeeping gene based on the $2^{-\Delta Ct}$ method, where ΔCt corresponds to the
11 formula $Ct_{\text{sample}} - Ct_{\text{housekeeping}}$.

12

13 **Plasma cytokine determinations**

14 Plasma obtained from our three cohorts of COVID-19 patients (n=45) was analyzed
15 using Ella® platform (Bio-Techne, Minneapolis, Minnesota, USA) for the quantification of the
16 following cytokines and chemokines: CCL2, GM-CSF, IL-10, IL-12 p70, IL-1ra, IL-6, IL-7, TNFa,
17 CXCL10, Granzyme B, IFN γ , IL-13, IL-15, IL-17A and IL-4. Samples were 1:2 diluted with sample
18 diluent provided by the manufacturer and loaded onto multiplex cartridges according to
19 manufacturer's instructions prior to their analysis. Results are expressed as pg/mL.

20

21 **Phenotyping and Intracellular Cytokine Staining in blood**

22 PBMCs were isolated from blood by density-gradient centrifugation using Ficoll-Paque and
23 immediately cryopreserved and stored in liquid nitrogen until use in the assays. Cells were thawed
24 the day before the assay and cultured in a T-25 flask at 37°C with RPMI 1640 (Gibco)
25 supplemented with 10% Fetal Bovine Serum (FBS) (Gibco), 100 μ g/ml streptomycin (Fisher
26 Scientific) and 100 U/ml penicillin (Fisher Scientific) (R10). Next day, previous to SARS-CoV-2
27 peptide pool stimulation, cells were stained for CCR7 (PE-CF594, BD Biosciences) and CXCR3
28 (BV650, BD Biosciences) for 30 min at 37°C. After a washing with PBS, PBMCs were stimulated
29 in a round bottom 96-well plate for 5h at 37°C with 1 μ g/ml of SARS-CoV-2 peptides (PepTivator
30 SARS-CoV-2 M, N and S, Miltenyi Biotec) in the presence of 1 μ l/ml of Brefeldin A (BD
31 Biosciences), 0.7 μ l/ml of Monensin (BD Biosciences) and 3 μ l/ml of α -CD28/CD49d (clones L293
32 and L25, BD Biosciences). Anti-CD107a (PE-Cy7, BD) was also added at this time. For each
33 patient, a negative control, cells treated with medium, and positive control, cells incubated in the
34 presence of 81nM PMA and 1 μ M Ionomycin, were included. After stimulation, cells were washed

1 twice with PBS and stained with Aqua LIVE/DEAD fixable dead cell stain kit (Invitrogen). Cell
2 surface antibody staining included anti-CD3 (Per-CP), anti-CD4 (BV605) and anti-CD56 (FITC)
3 (all from BD Biosciences). Cells were subsequently fixed and permeabilized using the
4 Cytotfix/Cytoperm kit (BD Biosciences) and stained with anti-Caspase-3 (AF647, BD Biosciences),
5 anti-Bcl-2 (BV421, Biolegend), anti-IL-4 (PE-Cy7, eBioscience), anti-IL-10 (PE, BD Biosciences)
6 and anti-IFN γ (AF700, Invitrogen) for 30 mins. Cells were then fixed with PBS 2% PFA and
7 acquired in a BD LSR Fortessa flow cytometer (Cytomics Platform, High Technology Unit, Vall
8 d'Hebron Institut de Recerca). FMO controls were used to draw the gates for each function.

9 For the patients with lung biopsies, their contemporary blood sample was processed
10 immediately and the T cell response assay was performed without a previous cryopreservation
11 step. Isolated PBMC were rested for 4h in the incubator and then stimulated with the same SARS-
12 CoV-2 peptides (M, N and S) overnight, following the same protocol described above with half
13 the amount of Brefeldin A and Monensin to avoid toxicity.

14

15 **Phenotyping and Intracellular Cytokine Staining in lung**

16 Lung biopsies were collected in antibiotic-containing RPMI 1640 medium from the Thoracic
17 Surgery Service at the Vall d'Hebron University Hospital. Immediately following surgery, the tissue
18 was dissected into approximately 8-mm³ blocks. These blocks were first enzymatically digested
19 with 5 mg/ml collagenase IV (Gibco) and 100 μ g/ml of DNase I (Roche) for 30 min at 37 °C and
20 400 rpm and, then, mechanically digested with a pestle. The resulting cellular suspension was
21 filtered through a 70 μ m pore size cell strainer (Labclinics), washed twice with PBS and cultivated
22 with R10 in a round-bottom 96-well plate overnight at 37°C with 1 μ g/ml of SARS-CoV-2 peptides
23 (M, N and S) in the presence of 3 μ L/mL α -CD28/CD49d (clones L293 and L25, BD Biosciences),
24 0.5 μ L/mL Brefeldin A (BD Biosciences), 0.35 μ L/mL Monensin (BD Biosciences) and 5 μ L/mL anti-
25 CD107a-PE-Cy5. For each patient, a negative control, cells treated with medium, and positive
26 control, cells incubated in the presence of 40.5nM PMA and 0.5 μ M Ionomycin, were included.
27 Next day, cellular suspensions were stained with Live/Dead Aqua (Invitrogen) and anti-CD103
28 (FITC, Biolegend), anti-CD69 (PE-CF594, BD Biosciences), anti-CD40 (APC-Cy7, Biolegend),
29 anti-CD8 (APC, BD Biosciences), anti-CD3 (BV650, BD Biosciences) and anti-CD45 (BV605, BD
30 Biosciences) antibodies. Cells were subsequently fixed and permeabilized using the FoxP3
31 Fix/Perm kit (BD Biosciences) and stained with anti-IL-4 (PE-Cy7, eBioscience), anti-IL-10 (PE,
32 BD Biosciences), anti-T-bet (BV421, Biolegend) and anti-IFN γ (AF700, Invitrogen) antibodies.
33 After fixation with PBS 2% PFA, cells were acquired in a BD LSR Fortessa flow cytometer.

34

1 **SARS-CoV-2 serology**

2 Serological status of HL24, HL27, HL52, HL65 and HL69 patients was determined in serum using
3 two commercial chemiluminescence immunoassays (CLIA) targeting specific SARS-CoV-2
4 antibodies: 1) Elecsys® Anti-SARS-CoV-2 (Roche Diagnostics, USA) was performed on the
5 Cobas 8800 system (Roche Diagnostics, USA) for qualitative determination of total antibodies
6 (including IgG, IgM and IgA) against nucleocapsid SARS-CoV-2 protein; and 2) Liaison SARS-
7 CoV-2 S1/S2 IgG (DiaSorin, Italy) was performed on the LIAISON® XL Analyzer (DiaSorin, Italy)
8 for quantitative determination of IgG against the spike (S) glycoprotein subunits 1 and 2 (S1/S2).

9

10 **SARS-CoV-2 detection by Immunofluorescence and RNA hybridization**

11 Paraffin-embedded lung tissue samples were processed and analyzed at the Pathology
12 Department of the HUVH. For SARS-CoV-2, lung tissue sections of 3µm were deparaffinized with
13 xylene and dehydrated in ethanol. Samples were pretreated with CC2 (pH=6), and rinsed with
14 working PBS. SARS-CoV-2 (SARS-CoV Nucleoprotein / NP Antibody, Rabbit PAb, 6F10, Sino
15 Biological, dilution at 1:1000) antibody was applied and incubated during 1h. After washing in
16 PBS, slides were mounted in 80% glycerol and sealed. Images were taken using BenchMark
17 Ultra Ventana System.

18 RNA hybridization was performed using RNAscope VS Universal Assays and the Ventana
19 Discovery Ultra System. A high sensitivity target-specific probes to SARS-CoV-2 mRNA
20 sequence (probe V-nCoV2019-S, ADC Biotecne biology) were used. Lung tissue sections of
21 3µm tissue sections were mounted on Superfrost Plus microscope slides (Fisher Scientific). The
22 assay was performed according to manufacturer's instructions. Briefly, samples were
23 deparaffinized and pretreated as mentioned. Next, probes were incubated for 2h at 40°C and
24 samples were stored overnight in 5x saline sodium citrate buffer. The following day, amplification
25 and signal development was performed by sequential incubation of Pre-Amplifiers, Amplifiers and
26 label probe according to the manufacturer's instructions (Kit DISCOVERY mRNA, Roche). Lastly,
27 samples were revealed with DAB staining (3,3'-Diaminobenzidine). The experiment controls used
28 were infected and non-infected HeLA cells.

29

30 **Statistical analyses**

31 Flow cytometry data was analyzed using FlowJo v10.7.1 software (TreeStar). Data and statistical
32 analyses were performed using Prism 7.0 (GraphPad Software, La Jolla, CA, USA), unless
33 otherwise stated. The statistical specifics of the experiments are provided in the respective figure
34 legends. Data plotted in linear scale were expressed as median + Interquartile (IQR) or Min to

1 Max range, unless otherwise stated. Correlation analyses were performed using Spearman rank
2 correlation. Mann-Whitney and Wilcoxon tests were applied for unpaired or paired comparisons,
3 respectively, while Kruskal-Wallis rank-sum test with Dunn's post hoc test was used for multiple
4 comparisons. A *P value* < 0.05 was considered significant. For most analyses, antigen-specific
5 T cell data has been calculated as the net frequency, where the individual percentage of
6 expression for a given molecule in the control condition (vehicle) has been subtracted from the
7 corresponding SARS-CoV-2-peptide stimulated conditions.

8

9 **ACKNOWLEDGMENTS**

10 We would like to thank all the patients who participated in the study. We also thank Prof. Shawn
11 C. Kefauver for thoughtful review of the manuscript. This work was primarily supported by a grant
12 from the Health department of the Government of Catalonia (DGRIS 1_5). This work was
13 additionally supported in part by the Spanish Health Institute Carlos III (ISCIII, PI17/01470 and
14 ISCIII COV20/00416), the Spanish Secretariat of Science and Innovation and FEDER funds
15 (grant RTI2018-101082-B-I00 [MINECO/FEDER]), the Spanish AIDS network Red Temática
16 Cooperativa de Investigación en SIDA (RD16/0025/0007), the European Regional Development
17 Fund (ERDF), the Fundació La Marató TV3 (grants 201805-10FMTV3 and 201814-10FMTV3)
18 and the Gilead fellowships GLD19/00084 and GLD18/00008. M.J.B is supported by the Miguel
19 Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). N.M. is supported
20 by a Ph.D. fellowship from the Vall d'Hebron Institut de Recerca (VHIR) and A.A-G and N.S-G
21 are supported by a Ph.D. fellowship from the Spanish Secretariat of Science and Innovation (BES-
22 2016-076382, PRE2019-087393). The funders had no role in study design, data collection and
23 analysis, the decision to publish, or preparation of the manuscript.

24

25 **AUTHOR CONTRIBUTIONS**

26 Conceptualization, MJ.B. and M.G.; Patient Recruitment and Sample Collection, J.R., A.T., B.P.,
27 J.N., P. S., AL.A., B.A., V.F., J.B.; Methodology, A.F., C.K., J.G-E., N. S-G., N.M., M. S., J.E.,
28 AN.A., and S.RC.; Investigation, J.G-E., N. S-G., N.M., M. S., A.A-G., D.P., D.A-S, I.S., J.E.,
29 AN.A. and M.G.; Formal Analysis, J.G-E., N. S-G., N.M., M. S., D. P. and M.G.; Writing-Original
30 Draft J.G-E., N. S-G., N.M., M. S. and M.G; Writing- Review & Editing, R.P-B., MJ.B. and M.G;
31 Funding Acquisition, MJ.B. and M.G.; all authors revised the manuscript; Supervision, MJ.B. and
32 M.G.

33

34 **DECLARATION OF INTEREST**

1 The authors declare no competing interest.

2 REFERENCES

- 3 1. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, *et al.* Clinical and immunological
4 assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* 2020, **26**(8): 1200-1204.
- 5 2. Mallapaty S. Will antibody tests for the coronavirus really change everything? *Nature*
6 2020, **580**(7805): 571-572.
- 7 3. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, *et al.* Convergent
8 antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* 2020,
9 **584**(7821): 437-442.
- 10 4. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, *et al.*
11 Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-
12 19. *Cell* 2020, **183**(1): 158-168 e114.
- 13 5. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory
14 coronaviruses. *Immunol Res* 2014, **59**(1-3): 118-128.
- 15 6. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, *et al.*
16 A systematic review of antibody mediated immunity to coronaviruses: kinetics,
17 correlates of protection, and association with severity. *Nature communications* 2020,
18 **11**(1): 4704.
- 19 7. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, *et al.* Robust
20 neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science* 2020.
- 21 8. Braun J, Loyal L, Frensch M, Wendisch D, Georg P, Kurth F, *et al.* SARS-CoV-2-
22 reactive T cells in healthy donors and patients with COVID-19. *Nature* 2020.
- 23 9. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, *et al.* Targets
24 of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease
25 and Unexposed Individuals. *Cell* 2020, **181**(7): 1489-1501 e1415.
- 26 10. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, *et al.* SARS-CoV-2-
27 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.
28 *Nature* 2020.
- 29 11. Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, *et al.* Detection of SARS-CoV-2-
30 Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.
31 *Immunity* 2020, **52**(6): 971-977 e973.
- 32 12. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, *et al.* Broad and strong memory
33 CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals
34 following COVID-19. *Nat Immunol* 2020.
- 35 13. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, *et al.*
36 Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and
37 Associations with Age and Disease Severity. *Cell* 2020.

- 1 14. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, *et al.*
2 Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute
3 respiratory distress syndrome. *Science immunology* 2020, **5**(48).
- 4
- 5 15. Channappanavar R, Fett C, Zhao J, Meyerholz DK, Perlman S. Virus-specific memory
6 CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome
7 coronavirus infection. *J Virol* 2014, **88**(19): 11034-11044.
- 8
- 9 16. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrancois L, Farber DL. Cutting edge:
10 Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus
11 infection. *Journal of immunology* 2011, **187**(11): 5510-5514.
- 12
- 13 17. Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, *et al.* Airway
14 Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory
15 Coronaviruses. *Immunity* 2016, **44**(6): 1379-1391.
- 16
- 17 18. Slutter B, Pewe LL, Kaech SM, Harty JT. Lung airway-surveilling CXCR3(hi) memory
18 CD8(+) T cells are critical for protection against influenza A virus. *Immunity* 2013, **39**(5):
19 939-948.
- 20
- 21 19. Kohlmeier JE, Woodland DL. Immunity to respiratory viruses. *Annu Rev Immunol* 2009,
22 **27**: 61-82.
- 23
- 24 20. Oja AE, Piet B, Helbig C, Stark R, van der Zwan D, Blaauwgeers H, *et al.* Trigger-happy
25 resident memory CD4(+) T cells inhabit the human lungs. *Mucosal Immunol* 2018, **11**(3):
26 654-667.
- 27
- 28 21. Woodland DL, Scott I. T cell memory in the lung airways. *Proc Am Thorac Soc* 2005,
29 **2**(2): 126-131.
- 30
- 31 22. Wu T, Hu Y, Lee YT, Bouchard KR, Benechet A, Khanna K, *et al.* Lung-resident memory
32 CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary
33 virus infection. *J Leukoc Biol* 2014, **95**(2): 215-224.
- 34
- 35 23. Pizzolla A, Nguyen TH, Sant S, Jaffar J, Loudovaris T, Mannering SI, *et al.* Influenza-
36 specific lung-resident memory T cells are proliferative and polyfunctional and maintain
37 diverse TCR profiles. *J Clin Invest* 2018, **128**(2): 721-733.
- 38
- 39 24. Groom JR, Luster AD. CXCR3 in T cell function. *Exp Cell Res* 2011, **317**(5): 620-631.
- 40
- 41 25. Pejoski D, Ballester M, Auderset F, Vono M, Christensen D, Andersen P, *et al.* Site-
42 Specific DC Surface Signatures Influence CD4(+) T Cell Co-stimulation and Lung-
43 Homing. *Front Immunol* 2019, **10**: 1650.
- 44
- 45 26. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, *et al.* Clinical and immunological
46 features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020, **130**(5):
47 2620-2629.
- 48
- 49 27. Chen Z, John Wherry E. T cell responses in patients with COVID-19. *Nat Rev Immunol*
50 2020, **20**(9): 529-536.
- 51

- 1 28. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A,
2 Antonakos N, *et al.* Complex Immune Dysregulation in COVID-19 Patients with Severe
3 Respiratory Failure. *Cell Host Microbe* 2020, **27**(6): 992-1000 e1003.
4
- 5 29. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, *et al.* Clinical features of patients infected
6 with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020, **395**(10223): 497-506.
7
- 8 30. Barathan M, Gopal K, Mohamed R, Ellegard R, Saeidi A, Vadivelu J, *et al.* Chronic
9 hepatitis C virus infection triggers spontaneous differential expression of biosignatures
10 associated with T cell exhaustion and apoptosis signaling in peripheral blood
11 mononucleocytes. *Apoptosis* 2015, **20**(4): 466-480.
12
- 13 31. Genesca M, Rourke T, Li J, Bost K, Chohan B, McChesney MB, *et al.* Live attenuated
14 lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific
15 CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus
16 replication after challenge with pathogenic SIVmac239. *Journal of immunology* 2007,
17 **179**(7): 4732-4740.
18
- 19 32. Tan YJ, Lim SG, Hong W. Regulation of cell death during infection by the severe acute
20 respiratory syndrome coronavirus and other coronaviruses. *Cell Microbiol* 2007, **9**(11):
21 2552-2561.
22
- 23 33. Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, *et*
24 *al.* Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response
25 through a HIF-1alpha/Glycolysis-Dependent Axis. *Cell Metab* 2020, **32**(3): 498-499.
26
- 27 34. Secinaro MA, Fortner KA, Dienz O, Logan A, Murphy MP, Anathy V, *et al.* Glycolysis
28 promotes caspase-3 activation in lipid rafts in T cells. *Cell Death Dis* 2018, **9**(2): 62.
29
- 30 35. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, *et al.* Lymphopenia predicts
31 disease severity of COVID-19: a descriptive and predictive study. *Signal transduction*
32 *and targeted therapy* 2020, **5**(1): 33.
33
- 34 36. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, *et al.* Immunology of COVID-
35 19: Current State of the Science. *Immunity* 2020, **52**(6): 910-941.
36
- 37 37. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodriguez L.
38 SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. *Cytokine Growth*
39 *Factor Rev* 2020, **54**: 62-75.
40
- 41 38. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, *et al.*
42 An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med*
43 2020, **26**(10): 1636-1643.
44
- 45 39. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, *et al.* Profiling serum cytokines in COVID-19
46 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect*
47 2020, **9**(1): 1123-1130.
48
- 49 40. Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, *et al.* Plasma IP-10 and MCP-3 levels
50 are highly associated with disease severity and predict the progression of COVID-19. *J*
51 *Allergy Clin Immunol* 2020, **146**(1): 119-127 e114.

- 1
- 2 41. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T
- 3 lymphocytes with distinct homing potentials and effector functions. *Nature* 1999,
- 4 **401**(6754): 708-712.
- 5
- 6 42. Kumar S. Caspase function in programmed cell death. *Cell Death Differ* 2007, **14**(1): 32-
- 7 43.
- 8
- 9 43. Bacher P, Rosati E, Esser D, Martini GR, Saggau C, Schiminsky E, *et al.* Low-Avidity
- 10 CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with
- 11 Severe COVID-19. *Immunity* 2020, **53**(6): 1258-1271 e1255.
- 12
- 13 44. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4(+) T cells in immunity to
- 14 viruses. *Nat Rev Immunol* 2012, **12**(2): 136-148.
- 15
- 16 45. Busatta Vaz de Paula C, Viola Azevedo ML, Nagashima S, Ana Paula Camargo Martins,
- 17 Mineia Alessandra Scaranello Malaquias, Anna Flavia Miggiolaro Ribeiro, *et al.* IL-4/IL-
- 18 13 Remodeling Pathway of Covid-19 Lung Injury. *Preprint at Research Square* 2020,
- 19 **DOI: 10.21203/rs.3.rs-34688/v1**.
- 20
- 21 46. Lakhani S, Flavell RA. Caspases and T lymphocytes: a flip of the coin? *Immunol Rev*
- 22 2003, **193**: 22-30.
- 23
- 24 47. Adamo S, Chevrier S, Cervia S, Zurbuchen Y, Raeber ME, Yang L, *et al.* Lymphopenia-
- 25 induced T cell proliferation is a hallmark of severe COVID-19. *Preprint at bioRxiv* 2020,
- 26 **<https://doi.org/10.1101/2020.08.04.236521>**.
- 27
- 28 48. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and
- 29 autoimmune disease. *Crit Rev Immunol* 2012, **32**(1): 23-63.
- 30
- 31 49. Bont L, Kavelaars A, Heijnen CJ, van Vught AJ, Kimpen JL. Monocyte interleukin-12
- 32 production is inversely related to duration of respiratory failure in respiratory syncytial
- 33 virus bronchiolitis. *The Journal of infectious diseases* 2000, **181**(5): 1772-1775.
- 34
- 35 50. Ferretti AP, Kula T, Wang Y, Nguyen DMV, Weinheimer A, Dunlap GS, *et al.* Unbiased
- 36 Screens Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in
- 37 SARS-CoV-2 that Largely Reside outside the Spike Protein. *Immunity* 2020.
- 38
- 39 51. Moguche AO, Shafiani S, Clemons C, Larson RP, Dinh C, Higdon LE, *et al.* ICOS and
- 40 Bcl6-dependent pathways maintain a CD4 T cell population with memory-like properties
- 41 during tuberculosis. *J Exp Med* 2015, **212**(5): 715-728.
- 42
- 43 52. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity,
- 44 inflammation and intervention. *Nat Rev Immunol* 2020, **20**(6): 363-374.
- 45
- 46 53. Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, *et al.* Deep
- 47 immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic
- 48 implications. *Science* 2020, **369**(6508).
- 49

- 1 54. Kallies A, Good-Jacobson KL. Transcription Factor T-bet Orchestrates Lineage
2 Development and Function in the Immune System. *Trends Immunol* 2017, **38**(4): 287-
3 297.
4
- 5 55. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The
6 transcription factor T-bet controls regulatory T cell homeostasis and function during type
7 1 inflammation. *Nat Immunol* 2009, **10**(6): 595-602.
8
- 9 56. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, *et al.* Dysregulation of Immune Response
10 in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* 2020,
11 **71**(15): 762-768.
12
- 13 57. Gong J, Dong H, Xia Q, 1 ZH, 1 DW, Yan, *et al.* Correlation Analysis Between Disease
14 Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia
15 *Preprint at medRxiv* 2020, <https://doi.org/10.1101/2020.02.25.20025643>.
16
- 17 58. Graham JB, Swarts JL, Menachery VD, Gralinski LE, Schafer A, Plante KS, *et al.*
18 Immune Predictors of Mortality After Ribonucleic Acid Virus Infection. *The Journal of*
19 *infectious diseases* 2020, **221**(6): 882-889.
20
- 21 59. Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to
22 viral infection by regulatory T cells. *Science* 2008, **320**(5880): 1220-1224.
23
- 24 60. Soerens AG, Da Costa A, Lund JM. Regulatory T cells are essential to promote proper
25 CD4 T-cell priming upon mucosal infection. *Mucosal Immunol* 2016, **9**(6): 1395-1406.
26
- 27 61. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during
28 acute influenza virus infection by producing IL-10. *Nat Med* 2009, **15**(3): 277-284.
29
- 30 62. Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, *et al.* Resolution of a
31 chronic viral infection after interleukin-10 receptor blockade. *J Exp Med* 2006, **203**(11):
32 2461-2472.
33
- 34 63. Turner DL, Farber DL. Mucosal resident memory CD4 T cells in protection and
35 immunopathology. *Front Immunol* 2014, **5**: 331.
36
- 37 64. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, *et al.* Single-cell landscape of
38 bronchoalveolar immune cells in patients with COVID-19. *Nat Med* 2020, **26**(6): 842-
39 844.
40
- 41 65. Gisondi P, S PI, Bordin C, Alaibac M, Girolomoni G, Naldi L. Cutaneous manifestations
42 of SARS-CoV-2 infection: a clinical update. *J Eur Acad Dermatol Venereol* 2020.
43
- 44 66. Skroza N, Bernardini N, Balduzzi V, Mambrin A, Marchesiello A, Michelini S, *et al.* A
45 late-onset widespread skin rash in a previous COVID-19-infected patient: viral or
46 multidrug effect? *J Eur Acad Dermatol Venereol* 2020.

FIGURE LEGENDS

1

2 **Figure 1. Functional characteristics of SARS-CoV-2-specific T cells by group and viral**
3 **protein.**

4 **(A)** Comparison of the net frequency (background subtracted) of IFN γ , CD107a, IL-4 and IL-10
5 expression in SARS-CoV-2-specific CD4⁺ and CD8⁺T cells in response to viral proteins
6 (membrane (M), nucleocapsid (N) and spike (S)) between study groups (non-hospitalized n=14
7 in orange; mild n=20 in purple and severe n=12 in pink). Statistical comparisons were performed
8 using Kruskal-Wallis rank-sum test with Dunn's multiple comparison test. *p<0.05, **p<0.01. **(B)**
9 Donut charts summarizing the contribution of each function to the overall CD4⁺ and CD8⁺ specific
10 T cell response by targeted viral protein and individual group of patients. Data represents the
11 mean value of the net frequency of each function indicated by color code considering all patients,
12 responders and non-responders. Total response value (%) is shown under each pie chart and
13 represents the cohort average of the overall net frequency considering all individuals and adding
14 up all functions (non-hospitalized n=14; mild n=20 and severe n=12). **(C)** Donut charts
15 summarizing the distribution of individual functions among specific-CD4⁺ and CD8⁺T cells to either
16 the M, N or S protein from the only fatal case within the severe COVID-19 group.

17

18 **Figure 2. T cell migratory patterns during acute SARS-CoV-2 infection.**

19 **(A and B)** The frequency of various T cell subsets defined by CCR7 and CXCR3 within CD4⁺ **(A)**
20 and CD8⁺T cells **(B)**. Each dot represents one patient of a specific cohort, indicated by color code
21 (normal donors n=12; non-hospitalized n=14; mild n=20 and severe n=12). Data are shown as
22 median and min to max range. Statistical comparisons were performed using Kruskal-Wallis rank-
23 sum test with Dunn's multiple comparison test. *p<0.05, **p<0.01, ***p<0.001. **(C)**
24 Representative flow cytometry plots gating the different CD8⁺T cell subsets in a non-hospitalized
25 (top) and a severe patient (bottom). **(D and E)** Correlations between days to discharge since
26 symptoms onset or IL-6 baseline levels and the frequency of CD8⁺ CCR7^hCXCR3^d **(D)** and CD8⁺
27 EM CXCR3⁺ **(E)** subpopulations. Spearman rank correlation (n=46).

28

29 **Figure 3. Migratory patterns of SARS-CoV-2-specific CD4⁺T cells expressing IFN γ , CD107a,**
30 **IL-4 or IL-10 by group and viral protein.**

31 **(A)** Net frequency of IFN γ , CD107a, IL-4 and IL-10 expression in SARS-CoV-2-specific CD4⁺ T
32 cells based on CXCR3⁺CCR7⁺ and CXCR3⁺CCR7⁻ subsets for each individual patient (non-
33 hospitalized n=14; mild n=20 and severe n=12). Viral proteins are shown in color green

1 (membrane protein, M), orange (nucleocapsid protein, N) and purple (spike protein, S). Dots
2 connected by the same line represent the same individual. Statistical comparisons were
3 performed using non-parametric Wilcoxon matched-pairs signed rank test to compare the two
4 groups (CXCR3+CCR7⁺ vs. CXCR3⁺CCR7⁻). *p<0.05, **p<0.01, ***p<0.001. **(B-D)** Correlation
5 between the days to discharge since symptoms onset or IL-6 and the frequency of nucleocapsid
6 or spike-specific CD4⁺ CXCR3⁺CCR7⁺ expressing IFN γ **(B)**, CD107a **(C)** or IL-4 **(D)**. **(E and F)**
7 Correlation between IL-6 and the frequency of membrane-specific CD4⁺ CXCR3⁺CCR7^{-/+}
8 expressing IFN γ **(E)** or IL-10 **(F)**. **(G)** Correlation between the viral load and the frequency of CD4⁺
9 EM CXCR3⁺ expressing IL-10 after PMA/Ionomycin stimulation. Spearman rank correlation (n=46
10 for all correlations except for viral load **(G)** which corresponds to n=33).

11
12 **Figure 4. IL-10 expression in SARS-CoV-2-specific CD8⁺T cell subsets during acute**
13 **infection.**

14 **(A)** Net frequency of IL-10 expression in CCR7⁺CXCR3⁻, CCR7⁺CXCR3⁺, CCR7^hCXCR3^d and
15 EM CXCR3⁺ subsets within CD8⁺ T cells after stimulation with any of the three viral proteins
16 (membrane (M), nucleocapsid (N) and spike (S) proteins). Data are shown as median and upper
17 range, where each dot represents an individual patient for each group (non-hospitalized n=14;
18 mild n=20 and severe n=12). Statistical comparisons were performed using Kruskal-Wallis rank-
19 sum test with Dunn's multiple comparison test. *p<0.05, **p<0.01. **(B-C)** Correlation between
20 CD8⁺ EM CXCR3⁺T cells responding with any function (added net response for IFN γ , CD107a,
21 IL-4 and IL-10) against M peptides and viral load **(B)** and against N peptides and baseline IL-6
22 levels **(C)**. Spearman rank correlation (n=33 for viral load and n=46 for IL-6).

23
24 **Figure 5. Pro-apoptotic caspase-3 expression in T cells during acute SARS-CoV-2**
25 **infection.**

26 **(A)** Frequency of caspase-3 expression in CD4⁺ and CD8⁺T cells after stimulation with membrane
27 (M), nucleocapsid (N) or spike protein (S) and PMA/Ionomycin, in non-hospitalized (orange,
28 n=14), mild (purple, n=20) and severe (pink, n=12) COVID-19 patients. **(B)** Correlation between
29 days to hospital discharge since symptoms onset, viral load or baseline IL-6 levels (pg/mL) and
30 the net frequency (background subtracted) of caspase-3 in CD4⁺ and CD8⁺T cells after stimulation
31 with the spike protein or PMA/Ionomycin. **(C)** Frequency of caspase-3 expression in CD8⁺
32 CCR7^hCXCR3^dT cells after stimulation. **(D)** Correlations between clinical parameters and the net
33 frequency of caspase-3 expression in CD8⁺ CCR7⁺ T cell subsets after stimulation. **(E)** Frequency
34 of caspase-3 expression in IL-10-secreting SARS-CoV-2-specific CD4⁺ and CD8⁺T cells

1 responding to the spike protein, the nucleocapsid protein or to PMA/Ionomycin. **(F)** Correlation
2 between clinical parameters and IL-10-expressing SARS-CoV-2-specific CD4⁺ or CD8⁺T cells, or
3 after PMA/Ionomycin stimulation. **(G)** Correlation between viral load and the frequency of caspase-
4 3 expression in basal CD107a⁺ degranulating CD4⁺T cells and between IL-6 and the net
5 frequency of caspase-3 expression in CD107a-expressing CD4⁺ in response to N peptides. Data
6 in graphs are shown as median and min to max range and statistical comparisons were performed
7 using Kruskal-Wallis rank-sum test with Dunn's multiple comparison test. *p<0.05, **p<0.01,
8 ***p<0.001, ****p<0.0001. Spearman rank correlation (n=46 for all correlations except for viral
9 load which corresponds to n=33).

10

11 **Figure 6. Functional analysis of lung-resident SARS-CoV-2-specific T cells.**

12 **(A and B)** Flow cytometry plots showing the frequency of IFN γ and degranulation (CD107a) by
13 non-T_{RM}, T_{RM} or CD103⁺ T_{RM} in CD4⁺ from HL27 after spike stimulation and control **(A)** and in
14 CD8⁺ from HL52 after nucleocapsid stimulation and control **(B)**. **(C)** Heatmaps summarizing the
15 net frequencies of IFN γ , CD107a, IL-4 and IL-10 SARS-CoV-2-specific CD4⁺ or CD8⁺ non-T_{RM},
16 T_{RM} and T_{RM} CD103⁺ from 5 different SARS-CoV-2 recovered patients. Cytokine production or
17 degranulation are displayed as colors ranging from yellow to blue, based on the frequency, as
18 shown in the key. **(D)** Net frequency of double positive IFN γ /CD107a CD3⁺T cells from lung or
19 blood after stimulation with membrane (M; green), nucleocapsid (N; orange) or spike protein (S;
20 purple).

21

22 **Figure 7. Comparison between SARS-CoV-2-specific T cells in lung and blood of** 23 **convalescent patients.**

24 **(A-D)** Total CD4⁺ and CD8⁺ T cell net frequencies of IFN γ , CD107a, IL-4 and IL-10 expression in
25 SARS-CoV-2-specific T cells derived from lung or blood from the same patient **(A)** (HL24), **(B)**
26 (HL52), **(C)** (HL65), **(D)** (HL69) and **(E)** (HL27). Viral proteins are shown in color green (membrane
27 protein, M), orange (nucleocapsid protein, N) and purple (spike protein, S).

28

Figure 1




Figure 2




Figure 3






Figure 4



B



C




Figure 5




Figure 6




Figure 7

